Mehta A, Rosenthal V D, Mehta Y, Chakravarthy M, Todi S K, Sen N, Sahu S, Gopinath R, Rodrigues C, Kapoor P, Jawali V, Chakraborty P, Raj J P, Bindhani D, Ravindra N, Hegde A, Pawar M, Venkatachalam N, Chatterjee S, Trehan N, Singhal T, Damani N
PD Hinduja National Hospital & Medical Research Centre, Mumbai, India.
J Hosp Infect. 2007 Oct;67(2):168-74. doi: 10.1016/j.jhin.2007.07.008. Epub 2007 Oct 1.
We sought to determine the rate of healthcare-associated infection (HCAI), microbiological profile, bacterial resistance, length of stay (LOS) and excess mortality in 12 ICUs of the seven hospital members of the International Infection Control Consortium (INICC) of seven Indian cities. Prospective surveillance was introduced from July 2004 to March 2007; 10 835 patients hospitalized for 52 518 days acquired 476 HCAIs, an overall rate of 4.4%, and 9.06 HCAIs per 1000 ICU-days. The central venous catheter-related bloodstream infection (CVC-BSI) rate was 7.92 per 1000 catheter-days;the ventilator-associated pneumonia (VAP) rate was 10.46 per 1000 ventilator-days; and the catheter-associated urinary tract infection (CAUTI) rate was 1.41 per 1000 catheter-days. Overall 87.5% of all Staphylococcus aureus HCAIs were caused by meticillin-resistant strains, 71.4% of Enterobacteriaceae were resistant to ceftriaxone and 26.1% to piperacillin-tazobactam; 28.6% of the Pseudomonas aeruginosa strains were resistant to ciprofloxacin, 64.9% to ceftazidime and 42.0% to imipenem. LOS of patients was 4.4 days for those without HCAI, 9.4 days for those with CVC-BSI, 15.3 days for those with VAP and 12.4 days for those with CAUTI. Excess mortality was 19.0% [relative risk (RR) 3.87; P < or = 0.001] for VAP, 4.0% (RR 1.60; P=0.0174) for CVC-BSI, and 11.6% (RR 2.74; P=0.0102) for CAUTI. Data may not accurately reflect the clinical setting of the country and variations regarding surveillance may have affected HCAI rates. HCAI rates, LOS, mortality and bacterial resistance were high. Infection control programmes including surveillance and antibiotic policies are a priority in India.
我们试图确定印度七个城市的国际感染控制联盟(INICC)的七家医院成员的12个重症监护病房(ICU)中的医疗保健相关感染(HCAI)发生率、微生物谱、细菌耐药性、住院时间(LOS)和额外死亡率。2004年7月至2007年3月引入前瞻性监测;10835名患者住院52518天,发生476例HCAI,总体发生率为4.4%,每1000个ICU日发生9.06例HCAI。中心静脉导管相关血流感染(CVC-BSI)发生率为每1000个导管日7.92例;呼吸机相关性肺炎(VAP)发生率为每1000个呼吸机日10.46例;导管相关性尿路感染(CAUTI)发生率为每1000个导管日1.41例。总体而言,所有金黄色葡萄球菌HCAI中87.5%由耐甲氧西林菌株引起,71.4%的肠杆菌科对头孢曲松耐药,26.1%对哌拉西林-他唑巴坦耐药;28.6%的铜绿假单胞菌菌株对环丙沙星耐药,64.9%对头孢他啶耐药,42.0%对亚胺培南耐药。无HCAI患者的住院时间为4.4天,CVC-BSI患者为9.4天,VAP患者为15.3天,CAUTI患者为12.4天。VAP的额外死亡率为19.0%[相对风险(RR)3.87;P≤0.001],CVC-BSI为4.0%(RR 1.60;P = 0.0174),CAUTI为11.6%(RR 2.74;P = 0.0102)。数据可能无法准确反映该国的临床情况,监测方面的差异可能影响了HCAI发生率。HCAI发生率、住院时间、死亡率和细菌耐药性都很高。包括监测和抗生素政策在内的感染控制计划是印度的优先事项。